Last Updated on October 17, 2024 by The Health Master
Granules India announced on Monday that it has received approval from the US Food and Drug Administration (USFDA) to market a generic product to treat high blood pressure.
According to Granules India, the US Food & Drug Administration (USFDA) has given the company the go-ahead to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg.
The Cozaar tablets produced by Organon LLC and manufactured by the Hyderabad-based company are bioequivalent.
According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million.
On the BSE, the company’s shares were trading 1.24 percent lower at Rs 281.75 per share.
USFDA gives nod for this generic drug to lower cholesterol levels
USFDA approves bleeding disorder therapy
USFDA issues EIR to Strides for Bangalore facility
Hyderabad is having maximum USFDA approved Pharma Units in world
USFDA gives tentative nod for Gabapentin Tablets, 300 mg and 600 mg
USFDA gives approval for Saxagliptin Tablets 2.5 mg and 5 mg
Saudi issues GMP certification to Venus remedies for Baddi facilities
Steep rise in prices of APIs hits Indian Pharma Companies
USFDA gives nod for this generic drug to lower cholesterol level
India’s first Biopharma Hub to be established in Telangana
Himachal gets first installment of Rs 225 cr for Bulk Drug Park
Show cause notices issued to 13 Ultrasound Centres
Govt firm on Ban of online sale of medicines
‘Chintan Shivir’ to be held with focus on Drug Quality Regulation and Enforcement
New DCGI: Rajeev Raghuvanshi appointed head of apex drug regulatory body
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
